江苏蓝丰生物化工股份有限公司 内部控制审计报告 2024 年度 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP 中国 . 江苏 . 无锡 Wuxi . Jiangsu . China 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要 求，我们审计了江苏蓝丰生物化工股份有限公司（以下简称"蓝丰生化"） 2024 年 12 月 31 日的财务报告内部控制有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内 部控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效 性是企业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效 性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 电子信箱：mail@gztycpa.cn E-mail：mail@g ...

江苏蓝丰生物化工股份有限公司 非经营性资金占用及其他关联资金往来情况的专项说明 2024 年度 Gongzheng Tianye Certified Public Accountants, SGP 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa. cn E-mail：mail@gztycpa. cn 关于江苏蓝丰生物化工股份有限公司 非经营性资金占用及其他关联资金往来情况的 专项说明 苏公W[2025]E1293号 苏州蓝丰生化料股份有限公司全体股东： 我们接受委托，按照中国注册会计师审计准则审计了江苏蓝丰生物化工股 份有限公司（以下简称"蓝丰生化"）财务报表，包括 2024 年 12 月 31 日的合并 及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流 量表、合并及母公司所有者权益变动表以及相关财务报表附注，并于 2025 年 4 月 27 日出具了苏公 W[2025]A686 号无保留意见审计报告。 公证天业会计师事务所(特殊普通合伙) ...

Business Focus and Structure - The company reported a significant change in its main business focus, shifting from "pharmaceutical health + pesticide chemicals" to "pesticide chemicals + photovoltaic new energy" after acquiring 51% of Anhui Xuhe Technology New Energy Co., Ltd. in October 2023[20]. - The company has undergone significant changes in its business structure, including the completion of a major asset restructuring involving the acquisition of Fangzhou Pharmaceutical in 2015[20]. - The company has entered the photovoltaic new energy sector through the acquisition of Xuhe Technology, establishing a dual business model of "agriculture + new energy" for future growth[97]. Financial Performance - The company's operating revenue for 2024 was CNY 1,793,141,048.95, representing a 2.96% increase compared to CNY 1,741,628,407.17 in 2023[22]. - The net profit attributable to shareholders for 2024 was a loss of CNY 252,500,773.62, an improvement of 24.01% from a loss of CNY 332,260,445.98 in 2023[22]. - The net cash flow from operating activities for 2024 was CNY 106,181,646.18, a significant increase of 127.70% compared to a negative cash flow of CNY 383,302,095.05 in 2023[22]. - The total assets at the end of 2024 were CNY 3,418,834,199.38, a slight increase of 0.57% from CNY 3,399,589,930.03 at the end of 2023[22]. - The net assets attributable to shareholders increased by 29.01% to CNY 32,536,860.02 at the end of 2024, up from CNY 25,221,286.52 at the end of 2023[22]. - The company reported a basic earnings per share of -CNY 0.6849 for 2024, which is a 23.14% improvement from -CNY 0.8911 in 2023[22]. Market and Industry Trends - The agricultural chemical industry showed a stable growth trend with a 22.2% year-on-year increase in the production of chemical pesticide raw materials in China for 2024[30]. - The company is navigating challenges from geopolitical conflicts and inflation pressures while maintaining a stable operational outlook[30]. - The photovoltaic market is transitioning from policy-driven to demand-driven, with a stable growth outlook for clean energy globally[39]. - The global photovoltaic market is expected to maintain a long-term growth trend, supported by stable policies and increasing demand in emerging markets[39]. Research and Development - The company is focusing on enhancing its core competitiveness through technological innovation and brand building in response to increasing industry uncertainties[30]. - The company is engaged in the research and development of efficient, low-toxicity pesticides, with competitive advantages in early market entry and established production technologies[43]. - The company has a robust R&D system, with over 100 patent applications filed during the reporting period, including 4 invention patents and 25 utility model patents granted[53]. - R&D investment surged to ¥68,680,051.26 in 2024, marking a 350.18% increase from ¥15,256,020.56 in 2023, representing 3.83% of operating revenue[75]. Environmental and Safety Compliance - The company is committed to environmental governance as a prerequisite for development, emphasizing the reduction of various pollutants[160]. - The company has implemented continuous upgrades in technology and equipment to reduce pollutant emissions, focusing on both source control and end-of-pipe treatment[160]. - The company has established a safety management department with 19 dedicated personnel, including 7 registered safety engineers[172]. - The company has completed 47 emergency drills in the reporting period, with no safety production accidents occurring[175]. Corporate Governance and Shareholder Relations - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective shareholder communication and rights[103]. - The company’s board includes independent directors, ensuring governance and oversight[113]. - The company plans to optimize the remuneration structure and strengthen incentive mechanisms to protect the interests of the company and all shareholders[124]. - The company has made commitments to maintain the legitimate rights and interests of all shareholders and will not engage in unfair benefit transfers[180]. Strategic Initiatives and Future Outlook - The company plans to enhance product diversity and competitiveness through the development of new technologies and products, including the TNP bifacial passivated solar cell[75]. - The company aims to increase the annual production capacity of its core product, with a target of 7,000 tons of a specific pesticide by optimizing production scheduling and enhancing operational standards[97]. - The company plans to continue optimizing channel resource allocation and enhancing marketing capabilities for its formulation products to prepare for market recovery[58]. - The company is focusing on market expansion, targeting new regions that could potentially increase market share by DD%[120].

Financial Performance - The company's revenue for Q1 2025 reached ¥543,942,036.72, representing a 43.86% increase compared to ¥378,109,304.42 in the same period last year[5]. - The net loss attributable to shareholders decreased to ¥22,154,823.78, a 27.38% improvement from a loss of ¥30,509,968.18 in the previous year[5]. - The net loss for the current period was ¥36,652,360.38, compared to a net loss of ¥42,479,148.33 in the previous period, indicating an improvement of approximately 13.5%[21]. - The company's weighted average return on equity improved to -98.31% from -275.86% year-on-year, reflecting a significant reduction in losses[5]. - The company reported a basic and diluted earnings per share of -0.0590, an improvement from -0.0825 in the previous period[21]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥131,618,672.70, worsening by 33.39% compared to a negative cash flow of ¥98,675,401.02 last year[5]. - Operating cash inflow for the current period was CNY 593,336,418.54, a slight increase from CNY 587,684,219.51 in the previous period[22]. - Cash inflow from financing activities totaled CNY 204,500,000.00, slightly down from CNY 205,136,621.05 in the previous period[23]. - The ending cash and cash equivalents balance was CNY 72,380,613.54, up from CNY 35,217,795.77 in the previous period[23]. - Cash received from investment activities was CNY 494,920.89, compared to CNY 36,200.00 in the previous period[22]. Assets and Liabilities - Total assets increased by 7.38% to ¥3,670,979,943.29 from ¥3,418,834,199.38 at the end of the previous year[5]. - Total liabilities increased to ¥3,392,534,886.30 from ¥3,106,254,842.30, which is an increase of approximately 9.2%[18]. - The company's total current assets increased to 1,572,989,951.02 yuan from 1,307,554,415.34 yuan, reflecting a growth of approximately 20.3%[16]. - The total equity attributable to shareholders of the parent company decreased to ¥12,532,821.11 from ¥32,536,860.02, a decline of about 61.5%[18]. - The total non-current liabilities amounted to ¥783,068,811.51, a slight increase from ¥773,176,926.83, reflecting a growth of approximately 1.3%[18]. Research and Development - Research and development expenses decreased by 41.43% to ¥15,858,510.05 from ¥27,074,326.90 in the previous year, indicating a reduction in R&D investment[10]. - Research and development expenses for the current period were ¥15,858,510.05, down from ¥27,074,326.90, representing a decrease of approximately 41.4%[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,951[12]. - The largest shareholder, Zheng Xu, holds 17.98% of the shares, totaling 67,457,432 shares, with 50,593,074 shares under lock-up and 33,500,000 shares pledged[12]. - The second-largest shareholder, Hainan Wenqin Private Equity Fund, holds 8.95% of the shares, totaling 33,589,000 shares, with 23,793,411 shares under lock-up[13]. Market and Operational Insights - The company reported a significant increase in sales revenue from photovoltaic cells and components, contributing to the overall revenue growth[10]. - The company is actively exploring market expansion strategies and new product development initiatives[15]. - Total operating costs increased to ¥588,744,587.62 from ¥440,095,408.26, reflecting a rise of about 33.7%[19]. Audit Information - The company did not undergo an audit for the first quarter report[24].

蓝丰生化控股子公司安徽旭合新能源科技有限公司根据与中新苏滁高新技术产业开发区管理委员会、中 新苏滁（滁州）开发有限公司签订的《"10GW超高效N型光伏电池及组件"项目补充协议书》相关条 款，近日收到固定资产投资补助款人民币21,462,209.00元，占上市公司最近一期经审计净资产85.10%， 补助形式为现金。上述补贴款系与资产相关的政府补助，旭合科技已收到该笔款项并确认为递延收益， 目前该笔政府补助具有可持续性。按照《企业会计准则第16号—政府补助》的规定，上述政府补助属于 与资产相关的政府补助，计入递延收益。旭合科技将在相关资产使用寿命内分期计入损益，主要机器设 备的使用期为10年。公司将根据相关法律法规及相关政府部门要求，合理合规地使用政府补助资金，实 现政府补助资金的高效使用。以上数据未经审计，具体的会计处理及对公司相关财务数据的影响以会计 师事务所年度审计确认后的结果为准，敬请广大投资者注意投资风险。 截至2025年3月28日收盘，蓝丰生化（002513）报收于4.36元，较上周的4.68元下跌6.84%。本周，蓝丰 生化3月27日盘中最高价报4.79元。3月24日盘中最低价报4.23元。蓝丰生化 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-008 江苏蓝丰生物化工股份有限公司 关于控股子公司获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 获得政府补助的基本情况 3、补助对上市公司的影响 本次收到的政府补助款旭合科技计入递延收益，在相关资产使用寿命内分期 1 计入损益（根据公司会计政策，旭合科技主要机器设备的使用期为 10 年）。 根据江苏蓝丰生物化工股份有限公司（以下简称"公司"）的控股子公司安徽 旭合新能源科技有限公司（以下简称"旭合科技"）与中新苏滁高新技术产业开 发区管理委员会、中新苏滁（滁州）开发有限公司签订的《"10GW 超高效 N 型光 伏电池及组件"项目补充协议书》相关条款，旭合科技于近日收到中新苏滁高新 技术产业开发区管理委员会下发的固定资产投资补助款人民币 21,462,209.00 元，占上市公司最近一期经审计净资产 85.10%，补助形式为现金。上述补贴款系 与资产相关的政府补助，旭合科技已收到该笔款项并确认为递延收益，目前该笔 政府补助具有可持续性。 二、 补助的类型及其对上市公司的 ...

本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、对外担保情况概述 江苏蓝丰生物化工股份有限公司（以下简称"公司"）分别于 2024 年 4 月 28 日及 2024 年 5 月 23 日召开第七届董事会第十二次会议、第七届监事会第九 次会议和 2023 年年度股东大会，会议审议通过了《关于预计 2024 年度为子公 司提供对外担保额度的议案》。为满足日常经营和业务发展的资金需要，公司 拟为安徽旭合新能源科技有限公司（以下简称"旭合科技"）融资事宜提供总 额不超过人民币 25 亿元的担保额度，该担保额度主要用于子公司融资、授信或 业务发展等需要。具体内容详见公司于 2024 年 4 月 30 日刊登在《上海证券报》、 《证券时报》、《中国证券报》和巨潮资讯网（www.cninfo.com.cn）上的《关 于预计 2024 年度为子公司提供对外担保额度的公告》（公告编号：2024-028）。 证券代码：002513 证券简称：蓝丰生化 公告编号：2025-007 江苏蓝丰生物化工股份有限公司 关于为控股子公司提供担保的进展公告 二、担保进展情况 近日，公司分别与 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-006 4、对公司损益产生的影响：本次诉讼尚未开庭审理，对本期利润及期后利 润的影响尚不确定。敬请广大投资者关注公司在指定信息披露媒体上披露的相关 公告，理性投资，注意投资风险。 一、本次诉讼事项受理的基本情况 江苏蓝丰生物化工股份有限公司 关于公司涉及诉讼的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、案件所处的诉讼阶段：法院已受理，尚未开庭 2、上市公司所处的当事人地位：被告 3、涉案金额：12,975,140 元 江苏蓝丰生物化工股份有限公司（以下简称"公司"或"蓝丰生化"）于近 日收到安徽省当涂县人民法院送达的案号为(2025)皖 0521 民初 737 号《传票》 和《民事起诉状》等相关法律文书，现将有关情况公告如下： 二、有关本案的基本情况 （一）诉讼各方当事人名称 原告：安徽国星生物化学有限公司（以下简称"国星生物"） 被告一：江苏蓝丰进出口有限公司 被告二：江苏蓝丰生物化工股份有限公司 （二）案件基本情况 原告与被告一于 2022 年 11 月 20 日签署《 ...

江苏蓝丰生物化工股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、基本情况 公司于 2024 年 7 月 19 日召开第七届董事会第十五次会议、第七届监事会第 十一次会议，审议通过了《关于向公司 2024 年限制性股票激励计划激励对象授 予限制性股票的议案》，根据公司 2024 年限制性股票激励计划实际授予结果， 公司分别于 2024 年 11 月 27 日、12 月 13 日召开第七届董事会第二十次会议、 2024 年第五次临时股东大会，审议通过了《关于变更注册资本、修订<公司章程> 并办理工商登记的议案》。具体详见 2024 年 11 月 28 日和 2024 年 12 月 14 日刊 登在公司指定信息披露网站巨潮资讯网（www.cninfo.com.cn）及《上海证券报》、 《证券时报》、《中国证券报》上的《第七届董事会第二十次会议决议公告》（公 告编号：2024-097）、《关于变更注册资本、修订<公司章程>并办理工商登记的 公告》（公告编号：2024-100）和《2024 年第五次临时股东大会决 ...

Financial Performance - The company expects a net loss attributable to shareholders of approximately 29 million to 21 million CNY, compared to a loss of 33.23 million CNY in the same period last year[2]. - The expected loss excluding non-recurring gains and losses is projected to be between 27 million to 19 million CNY, down from a loss of 36.13 million CNY year-over-year[2]. - Basic earnings per share are anticipated to be a loss of 0.79 to 0.57 CNY per share, compared to a loss of 0.89 CNY per share in the previous year[2]. Asset Impairment and Provisions - The company has recognized asset impairment provisions totaling approximately 68 million CNY, impacting the net profit significantly[4]. - Non-recurring gains and losses are primarily related to provisions for expected liabilities from a terminated agreement and litigation outcomes, estimated to impact net profit by about 31.5 million CNY[5]. Market Conditions - The agricultural chemicals segment faced low market demand, leading to a decline in sales prices and gross profit margins[4]. - The photovoltaic segment experienced intensified market competition, resulting in significant losses despite a substantial increase in product shipment volumes[4]. Reporting and Audit - The financial data presented is preliminary and subject to audit, with final figures to be disclosed in the 2024 annual report[6].